RATINGS CHANGES

Abbott Laboratories (ABT) - Get Report was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: ABT.

Actuant (ATU) was upgraded to overweight from sector weight at Keybanc. $32 price target. The new CEO is making positive changes and the industrial business appears to be rebounding, Keybanc said. 

IberiaBank (IBKC) - Get Report was upgraded to outperform from market perform at JMP Securities. $94 price target. Sabadell acquisition will add to earnings, JMP said. 

Ionis Pharma (IONS) - Get Report was downgraded to sell from neutral at Goldman Sachs. $25 price target. There are questions on the market viability of two products in Phase 3 trials, Goldman said. 

Kimberly-Clark (KMB) - Get Report was downgraded to hold from buy at Societe Generale. $144 price target. The company is facing increased price competition, Societe said. 

Luminex (LMNX) - Get Report was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: LMNX.

Loxo Oncology (LOXO) - Get Report was downgraded to neutral at Citigroup. The valuation is less attractive, based on a $45 price target, Citi said. 

Mednax (MD) - Get Report was downgraded to neutral from overweight at JPMorgan. The valuation is more attractive, based on a $69 price target, JPMorgan said. 

This article was written by a staff member of TheStreet.